Mendus

What Mendus does

Mendus AB (publ) is a clinical-stage biopharmaceutical company headquartered in Stockholm, Sweden, with research and development operations in Leiden, The Netherlands, and is publicly listed on NASDAQ Stockholm under the ticker IMMU.ST. The company develops off-the-shelf, allogeneic cell-based immunotherapies designed to address tumor recurrence — the principal cause of cancer-related mortality — in hematological malignancies and ovarian cancer. Its lead product, vididencel (DCP-001), is an allogeneic dendritic cell therapy engineered to prime the patient's immune system against residual leukemic and ovarian cancer cells, with active clinical programs in acute myeloid leukemia (ALISON supporting data), chronic myeloid leukemia (VITAL-CML, first patient enrolled April 2026), and high-risk ovarian cancer (ALISON long-term follow-up, five participants progression-free including two beyond 3.5 years).

The company is built on a proprietary DCOne platform, originally developed for dendritic cell therapies and now also being explored as a source for high-quality NK (natural killer) cell therapies, providing a potential second product line. Manufacturing is secured through a strategic CDMO partnership with NorthX Biologics, which achieved GMP certification for vididencel production in December 2025, enabling late-stage clinical and prospective commercial supply. The company was formed in November 2020 through the merger of Immunicum AB and DCprime, subsequently rebranded from Immunicum to Mendus in 2024, and has funded operations to date primarily through equity, convertible notes, and shareholder loans (most recently SEK 52.5 million raised in November 2025).

Mendus is pre-revenue, with no commercialized products. Its planned go-to-market model is sales-led via strategic partnerships, co-development, or licensing arrangements with larger pharmaceutical companies rather than building an independent commercial sales organization. Edison's analysis has adjusted the licensing timeline for vididencel to early 2027, framing a partnership transaction as the principal near-term value realization path. The addressable end-user base is oncology departments, hematology clinics, and clinical trial sites treating patients with AML, CML, and ovarian cancer, while the direct paying customers in the near term are expected to be licensing partners rather than healthcare providers.

Name

Mendus

Legal name

Mendus AB (publ)

Website

https://mendus.com

Company type

Public

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Mendus is a clinical-stage biopharmaceutical company developing off-the-shelf allogeneic dendritic cell immunotherapies, principally vididencel, to prevent tumor recurrence in acute myeloid leukemia, chronic myeloid leukemia, and ovarian cancer patients, with planned licensing transactions targeted for early 2027.

Ownership category

akta.pro rank

Product category

Cancer Immunotherapy Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Dendritic Cell & Other APC-based Therapies (HLAAABAF)

akta.pro secondary industries

Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables) (HLAAABAH), Cell Therapy Manufacturing Services (GMP, autologous/allogeneic) (HLAAAKAC), Cell Therapy CDMO (Autologous/Allogeneic Manufacturing) (HLAGAGAA)

Keywords

• Cell-based immunotherapy
• Cancer maintenance therapy
• Dendritic cell therapy
• Acute myeloid leukemia
• Chronic myeloid leukemia

Headquarters

HQ city

Stockholm

HQ country

Sweden

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Others

Revenue model

1. Pharmaceutical Product Sales: Pre-revenue clinical-stage biopharmaceutical company developing cell-based immunotherapies. The company has not yet commercialized any products. Revenue is expected from future product sales following regulatory approval.
2. Licensing and Partnership Revenue: Edison report indicates Mendus expanded its strategy for vididencel in treating leukemia. Licensing timeline adjusted to early 2027, suggesting strategic partnerships or licensing agreements as potential revenue sources.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Mendus is a clinical-stage biopharmaceutical company developing off-the-shelf, allogeneic dendritic cell-based immunotherapies for cancer. Its lead product vididencel (DCP-001) is being developed as a maintenance therapy for hematological malignancies including acute myeloid leukemia (AML) and chronic myeloid leukemia (CML), as well as ovarian cancer, with the goal of reducing tumor recurrence by priming the immune system against residual cancer cells.

Product overview

Mendus is a biopharmaceutical company developing off-the-shelf, allogeneic cell-based immunotherapies for cancer treatment. The company's core product is vididencel, an allogeneic dendritic cell therapy targeting hematological malignancies including acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Mendus leverages its proprietary DCOne platform technology, originally developed for dendritic cell therapies and now also being used as a source for NK cell therapies. The company is also advancing DCP-001, a therapy derived from the DCOne platform. The product portfolio is focused on addressing tumor recurrence and improving survival outcomes while preserving quality of life for cancer patients.

Differentiator

Problem solved

Functional benefit

Products and services

• Vididencel (DCP-001)
• DCOne Platform

Quantifiable outcome

• ALISON trial: Five participants remained progression-free at long-term follow-up, including two beyond 3.5 years
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• NorthX BiologicscoreStrategic or Co-development Partner · 1 December 2025NorthX Biologics achieved GMP certification to manufacture vididencel, Mendus's off-the-shelf cell therapy for acute and chronic myeloid leukemias (AML and CML). This partnership enables the therapy to advance into late-stage clinical trials, with NorthX providing manufacturing infrastructure and expertise as a CDMO (contract development and manufacturing organization). The milestone reinforces Sweden's position as a key hub for advanced therapy medicinal products (ATMPs) and brings Mendus closer to commercialization.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Regional players

• Celyad Oncology: Belgian clinical-stage cell therapy company developing CAR T-cell therapies for hematological malignancies. Comparable to Mendus as a European-headquartered, small-cap clinical cell therapy developer with overlapping indication focus, though Celyad is autologous-focused.

Broad incumbents

• Adaptimmune Therapeutics: Clinical and commercial cell therapy company developing engineered TCR T-cell therapies for solid tumors. Comparable as a public cell therapy company targeting cancer with a similar clinical-stage profile and partnership-driven commercialization model, but with a different cell engineering modality.
• Iovance Biotherapeutics: Commercial-stage leader in tumor-infiltrating lymphocyte (TIL) cell therapy for solid tumors. Comparable to Mendus as a cell therapy company in oncology, but with an autologous (vs Mendus's allogeneic) approach and an already-approved product, making it a broader incumbent reference point.

Direct peers

• Allogene Therapeutics: Clinical-stage biotech developing allogeneic CAR T-cell therapies for hematological cancers. Most comparable to Mendus on the allogeneic cell therapy modality, off-the-shelf positioning, and hematological malignancy focus, though Allogene targets different antigens and indications.
• Nkarta: Developer of allogeneic NK cell therapies for cancer, with lead programs in B-cell malignancies and autoimmune diseases. Comparable to Mendus through its off-the-shelf NK cell platform (overlapping with Mendus's DCOne platform extension into NK cell therapies) and hematological cancer focus.
• Fate Therapeutics: Clinical-stage developer of off-the-shelf, iPSC-derived NK and T-cell cancer immunotherapies. Comparable to Mendus on the allogeneic, off-the-shelf cell therapy platform approach and on targeting hematological malignancies with engineered immune cell products.
• Atara Biotherapeutics: Allogeneic T-cell and NK cell therapy developer with clinical programs in hematological malignancies and solid tumors. Comparable to Mendus through its allogeneic cell therapy platform, off-the-shelf manufacturing approach, and focus on post-transplant and oncology maintenance settings.

Others

• Cellectis: French clinical-stage gene-editing and allogeneic CAR T platform company. Comparable to Mendus as an enabler/platform participant in the allogeneic cell therapy ecosystem, with a similar European footprint and similar clinical-stage commercial trajectory.

Emerging players

• Precision BioSciences: Clinical-stage biotech developing allogeneic CAR T and in vivo gene editing therapies. Comparable as a small-cap clinical-stage allogeneic cell therapy developer with a similar partnership/licensing go-to-market approach and hematological cancer focus.
• Marker Therapeutics: Clinical-stage company developing multi-tumor-associated antigen (multiTAA)-specific T-cell therapies for hematological malignancies. Comparable to Mendus in clinical-stage cell therapy development targeting leukemia/lymphoma with non-engineered, multi-antigen immune cell approaches.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/mendus
• Xx.com/mendus_ab

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mendus